Navigation Links
Saliva gland test for Parkinson's shows promise, study finds
Date:1/10/2013

PHOENIX Described as a "big step forward" for research and treatment of Parkinson's disease, new research from Mayo Clinic in Arizona and Banner Sun Health Research Institute suggests that testing a portion of a person's saliva gland may be a way to diagnose the disease. The study was released today and will be presented at the American Academy of Neurology's annual meeting in San Diego in March.

"There is currently no diagnostic test for Parkinson's disease," says study author Charles Adler, M.D., Ph.D., a neurologist with Mayo Clinic in Arizona. "We have previously shown in autopsies of Parkinson's patients that the abnormal proteins associated with Parkinson's are consistently found in the submandibular saliva glands, found under the lower jaw. This is the first study demonstrating the value of testing a portion of the saliva gland to diagnose a living person with Parkinson's disease. Making a diagnosis in living patients is a big step forward in our effort to understand and better treat patients."

The study involved 15 people with an average age of 68 who had Parkinson's disease for an average of 12 years, responded to Parkinson's medication and did not have known saliva gland disorders. Biopsies were taken of two different saliva glands: the submandibular gland and the minor saliva glands in the lower lip. The surgical team was led by Michael Hinni, M.D., and David Lott, M.D., at Mayo Clinic in Arizona, and the biopsied tissues were tested for evidence of the abnormal Parkinson's protein by study co-author Thomas Beach, M.D., with Banner Sun Health Research Institute.

"This procedure will provide a much more accurate diagnosis of Parkinson's disease than what is now available," Dr. Beach says. "One of the greatest potential impacts of this finding is on clinical trials, as at the present time some patients entered into Parkinson's clinical trials do not necessarily have Parkinson's disease and this is a big impediment to testing new therapies."

The abnormal Parkinson's protein was detected in nine of the 11 patients who had enough tissue to study. While still being analyzed, the rate of positive findings in the biopsies of the lower lip glands appears much lower than for the lower jaw gland.

"This study provides the first direct evidence for the use of submandibular gland biopsies as a diagnostic test for living patients with Parkinson's disease," Dr. Adler. "This finding may be of great use when needing definitive proof of Parkinson's disease, especially when considering performing invasive procedures such as deep brain stimulation surgery or gene therapy."

Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. But while tremor may be the best-known sign of Parkinson's, the disorder also commonly causes stiffness or slowing of movement. Currently, diagnosis is made based on medical history, a review of signs and symptoms, a neurological and physical examination, and by ruling out other conditions. Up to 30 percent of patients may be misdiagnosed early in the disease.

Although Parkinson's disease can't be cured, medications may markedly improve symptoms.


'/>"/>

Contact: Jim Mcveigh
mcveigh.jim@mayo.edu
480-301-4368
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Saliva test could dramatically increase detection of oral cancer
2. Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
3. Researchers aim to grow salivary glands using patients own cells
4. Sensor detects glucose in saliva and tears for diabetes testing
5. First gene therapy study in human salivary gland shows promise
6. Red Tide Likely in New England This Season, Experts Warn
7. Researchers see BPA effects in monkey mammary glands
8. Newborn Screening May Miss Adrenal-Gland Disorder
9. New England Journal of Medicine hails new skin cancer drug as greatest advance yet
10. Aetna Institute Designates RSC New England Center of Excellence
11. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: